STAT+: Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines
STAT
APRIL 3, 2024
LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. It’s run into some hurdles as it’s pioneered turning mRNA — the strand of genetic material that’s at the heart of Moderna’s approach — into medicines.
Let's personalize your content